domingo, 15 de noviembre de 2009

(1) Transfusion guidelines for neonates and older children. (2) Amendments and corrections to the transfusion guidelines


GUIDELINE TITLE
(1) Transfusion guidelines for neonates and older children. (2) Amendments and corrections to the transfusion guidelines for neonates and older children.

BIBLIOGRAPHIC SOURCE(S)
Boulton F, BCSH Transfusion Task Force. Amendments and corrections to the 'transfusion guidelines for neonates and older children'. London (UK): British Committee for Standards in Haematology (BCSH); 2005 Dec 7. 5 p. [9 references]

Gibson BE, Todd A, Roberts I, Pamphilon D, Rodeck C, Bolton-Maggs P, Burbin G, Duguid J, Boulton F, Cohen H, Smith N, McClelland DB, Rowley M, Turner G, British Committee for Standards in Haematology Transfusion Task Force: Writing Group. Transfusion guidelines for neonates and older children. Br J Haematol 2004 Feb;124(4):433-53. [113 references] PubMed


GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references drugs for which important revised regulatory information has been released.

Drug Withdrawal

May 14, 2008 - WITHDRAWAL: Trasylol (aprotinin injection): Following publication of the Blood conservation using antifibrinolytics: A randomized trial in a cardiac surgery population (BART) study in the May 14, 2008 online issue of The New England Journal of Medicine, Bayer Pharmaceuticals notified the U.S. Food and Drug Administration (FDA) of their intent to remove all remaining supplies of Trasylol from hospital pharmacies and warehouses. Because Trasylol has been shown to decrease the need for red blood cell transfusions in patients undergoing coronary artery bypass surgery, future supplies of Trasylol will continue to be available through the company as an investigational drug under a special treatment protocol.
Additional Notice

July 31, 2008, Erythropoiesis Stimulating Agents (ESAs): Amgen and the U.S. Food and Drug Administration (FDA) informed healthcare professionals of modifications to certain sections of the Boxed Warnings, Indications and Usage, and Dosage and Administration sections of prescribing information for Erythropoiesis Stimulating Agents (ESAs). The changes clarify the FDA-approved conditions for use of ESAs in patients with cancer and revise directions for dosing to state the hemoglobin level at which treatment with an ESA should be initiated.

abrir aquí para acceder al documento NGC AHRQ completo:
(1) Transfusion guidelines for neonates and older children. (2) Amendments and corrections to the transfusion guidelines

No hay comentarios:

Publicar un comentario